Proto Labs’s (NYSE:PRLB) Q4 Sales Beat Estimates But Stock Drops
  • February 7, 2025

Proto Labs’s (NYSE:PRLB) Q4 Sales Beat Estimates But Stock Drops

Manufacturing services provider Proto Labs (NYSE:PRLB) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 2.6% year on year to $121.8 million. On the other hand, next quarter’s revenue guidance of $124 million was less impressive, coming in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.38 per share was 18.8% above analysts’ consensus estimates.

The markets left reeling from Trump's tariff threats
  • February 7, 2025

The markets left reeling from Trump's tariff threats

U.S. President Donald Trump's ability to swiftly impose, and then delay, tariffs on top trading partners has left world markets swinging one way and then another. Last weekend, for example, he announced sweeping tariffs on Canada, Mexico and China, and then on Monday he announced one-month delays for Canada and Mexico.

L'Oreal takes stakes in Chinese, N.American clinics to understand medical aesthetics market
  • February 6, 2025

L'Oreal takes stakes in Chinese, N.American clinics to understand medical aesthetics market

L'Oreal has taken stakes in clinics in China and North America in order to observe and understand the medical aesthetics market, L'Oreal CEO Nicolas Hieronimus said in an earnings call on Friday. The company had announced in August the acquisition of a 10% stake in Swiss skin care firm Galderma. Hieronimus added that L'Oreal would be entering the nutricosmetics market with a new product and said more would be coming.

3 Reasons ZM is Risky and 1 Stock to Buy Instead
  • February 6, 2025

3 Reasons ZM is Risky and 1 Stock to Buy Instead

Zoom has been on fire lately. In the past six months alone, the company’s stock price has rocketed 56%, reaching $86.90 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

3 Reasons CRI is Risky and 1 Stock to Buy Instead
  • February 6, 2025

3 Reasons CRI is Risky and 1 Stock to Buy Instead

Over the past six months, Carter’s stock price fell to $50.45. Shareholders have lost 17.4% of their capital, which is disappointing considering the S&P 500 has climbed by 16.8%. This might have investors contemplating their next move.